"Designing Growth Strategies is in our DNA"

Orphan Drugs Market Size, Share & COVID-19 Impact Analysis, By Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Infectious Diseases, and Others), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and Regional Forecast, 2023-2030

Region : Global | Format: PDF | Report ID: FBI100088

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The orphan drugs market size was valued at USD 156.97 billion in 2022 and is projected to grow from USD 170.49 billion in 2023 to USD 368.43 billion by 2030, exhibiting a CAGR of 11.6% during 2023-2030. North America dominated the global market with a share of 53.88% in 2022.


Orphan drugs are developed by the pharmaceutical industry for economic reasons but respond to the public health needs. These drugs are developed to treat patients suffering from serious diseases for which no treatment, or at least a satisfactory one, has so far been available. For instance, an article published by the Orphanet in 2023 stated that the number of rare diseases for which no treatment is currently available is estimated to be between 4,000 and 5,000 globally. Moreover, 25 to 30 million people are reported to be affected by these rare diseases in Europe.


According to the European Organization for Rare Diseases, orphan drugs are produced for diagnosis, prevention, and treatment of rare disorders. The oncology therapy area holds a considerably higher share in the global market due to emergence of new cancer-related diseases. Additionally, FDA approvals to a series of cancer-related orphan drugs are expected to result in increased commercialization of these drugs, especially in the oncology therapy area, during the forecast period. The market will derive growth from higher demand for immunomodulators, as they regularize or amplify the immune system. Rising prevalence of infectious diseases in developed as well as emerging nations and higher prices of medications are projected to fuel the demand for immunomodulators, thus contributing to the global orphan drugs market growth during the forecast period.


COVID-19 IMPACT


The increase in Regulatory Approvals During COVID-19 Pandemic Impacted the Market Growth Positively  


The impact of the COVID-19 pandemic on certain markets in the pharmaceutical industry was more pronounced due to the postponement of the diagnosis and treatment of non-life-threatening diseases. This was especially true for individuals suffering from rare diseases as more financial and healthcare resources by various governments were directed toward fighting the pandemic.



  • For instance, a report by TransUnion Healthcare estimated a 32-60% decrease in outpatient hospital visits in March 2020 for over 500 hospitals across the United States. This affected individuals suffering from rare diseases as the lack of diagnostic and consulting services by healthcare professionals would impact the timely prescription of orphan medicines.


However, as per RwHealth article published in 2023, despite the challenges compounded by the COVID-19 pandemic while conducting clinical research in orphan diseases, the average number of applications seeking permission for marketing of orphan medicinal products sent to the European Medicine Agency (EMA) during COVID-19, i.e., 2020 – 2021, were higher as compared to the pre-pandemic period.


In 2021, the growth of the market continued primarily due to resumption in research and development activities of market players.



  • As per a 2022 report of Evaluate Pharma, the global orphan drugs sale of Vertex Pharmaceuticals was USD 7.2 billion and is estimated to record 7.1% CAGR to reach USD 10.1 billion by 2026.


This growth is expected to be continued during forecast period, owing to launches of various pipeline candidates for various indications by key players. Such trends indicate that the market is poised for steady growth during the forecast period.


LATEST TRENDS


Request a Free sample to learn more about this report.


Strong Product Launches to Drive Market Growth


Globally, patients suffering from rare diseases are seeking efficient and potent treatment for these disorders. Increasing R&D initiatives and rising advocacy by patients’ groups for effective treatment are propelling the introduction of newer and more effective product offerings. These trends have led to the development and marketing of several blockbuster drugs for the treatment of many types of cancers, immunological diseases, and other rare disorders.



  • As per the Orphan Drug Report 2022 by Evaluate Pharma, it is estimated that the rise of top 10 orphan drugs blockbusters will be worth between USD 3 billion and USD 13 billion by 2026. Furthermore, it estimated that 40% of Johnson & Johnson’s pharmaceutical sales will come from orphan drugs, especially through blood cancer drugs, such as Imbruvica and Darzalex, which is expected to be worth over USD 23 billion by 2026. Thus, the introduction of such sophisticated orphan therapeutics by established and emerging companies have been instrumental in boosting the adoption of these drugs, which is expected to aid the growth of the global market during the forecast period.


DRIVING FACTORS


Increasing R&D Initiatives to Drive Market Growth


One of the critical driving factors prevailing in the global market is the increasing R&D investments by prominent players for the development of novel products. Since the awareness and understanding regarding rare diseases has increased, a number of key clinical stage biopharmaceutical companies and established market players are creating strong pipeline candidates for orphan drugs in various stages of clinical trials. This increasing foray into rare disorder therapeutics is due to the reason that major pharmaceutical breakthroughs resulting in the development of blockbuster drugs are quite possible in rare disorders in comparison to the traditional pharmaceutical portfolios.



  • In 2021, over half of FDA’s Center for Drug Evaluation and Research (CDER) approvals had orphan designation and two CAR-T cell therapies were approved by the Center for Biologics Evaluation and Research (CBER).


Another strong driver for this is that pharmaceutical companies are required to conduct larger outcome studies for the regulatory approvals of traditional therapeutics for diseases, such as diabetes and Coronary Artery Disease (CAD) in comparison to rare diseases. This factor is projected to propel the market growth during the forecast period.


Growing Patient Population with Rare Diseases is Propelling Market Development


Strong research and development initiatives for rare disease therapeutics are expected to have a significant positive impact on the global market. According to an article published by Euronews in 2023, there are 5,000 to 8,000 rare diseases in Europe and affects the daily life of almost 30 million people in the region and 300 million across the world. This has created a sizable patient population who have significantly unmet clinical needs, which are extremely serious in nature. Hence, growing investment in R&D and increasing involvement of major and emerging market players in the development of sophisticated and effective products are expected to boost the market growth.


RESTRAINING FACTORS


High Cost Associated with Orphan Drugs to Limit their Adoption


Despite the increasing focus on the development and marketing of rare disease therapeutics globally, certain limitations are restricting the global market growth. One of the critical restraining factors is the high costs associated with these drugs.



  • As per a news article published by USA Today in 2023, Zolgensma, a one-time treatment approved for treating spinal muscular atrophy is among the highest priced drugs in the U.S. market. The drugs costs around USD 2.25 million and has treated more than 3,000 patients globally.


Such high cost of treatments has significantly limited the adoption of these products, especially in emerging countries. Such high costs are also a cause of concern for the developed countries where many of the drugs may not be adequately reimbursed, thus significantly increasing a patient’s out-of-pocket costs.


SEGMENTATION


By Therapy Area Analysis


To know how our report can help streamline your business, Speak to Analyst


Oncology Segment to Dominate due to Robust Regulatory Drug Approvals


On the basis of therapy area, the market is classified into oncology, hematology, neurology, endocrinology, cardiovascular, respiratory, immunotherapy, infectious diseases, and others.


The oncology segment held a dominant orphan drugs market share in 2022. The dominance is due to the presence of several oncology drugs in the product development pipelines of key players and presence of a large number of orphan drugs dedicated to the treatment of various cancers. For instance, in February 2022, CTI BioPharma received the U.S. FDA approval for its drug Pacritinib for the treatment of adult patients with myelofibrosis, a rare bone cancer affecting over 21,000 patients in the U.S.


The hematology segment is projected to be the second most dominant segment owing to a number of new product launches and increasing number of regulatory approvals. The neurology segment is also anticipated to register a comparatively strong CAGR due to positive developments in the product offerings for chronic diseases, such as multiple sclerosis.


However, the endocrinology, respiratory, and cardiovascular segments are anticipated to register lower CAGRs during the forecast period. The immunotherapy segment is expected to register a strong CAGR due to the presence of reliable products, such as Keytruda, and also increased research initiatives.


By Drug Type Analysis


Biologics Segment Dominated Due to Strong Product Offerings


Based on drug type, the market is segmented into biologics and non-biologics.


The biologics segment dominated the global market share in 2022 due to the overwhelming presence of product offerings classified as biologics. According to an estimate by the U.S. Food and Drug Administration (FDA), the Office of Orphan Products Development (OOPD) of the organization has developed and marketed over 600 drugs and biologic products to treat rare disorders since 1983. The non-biologics segment accounted for a lower share of the global market and also registered a comparatively low CAGR.


By Distribution Channel Analysis


High Accessibility toward Hospital Pharmacies Led to Segment Dominance


On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.


The hospital pharmacy segment is expected to hold the largest market share during the forecast period. The primary reason behind the segment’s dominance is that a significantly large number of drugs have to be administered at hospitals intravenously by trained healthcare professionals. The retail pharmacy segment is expected to register a comparatively lower CAGR during the forecast period.


The online pharmacy segment is expected to register a high CAGR due to the ease given to consumers while buying drugs. Also, during the COVID-19 pandemic, online pharmacies registered strong growth due to the increasing number of consumers switching to online pharmacies to purchase these drugs.


REGIONAL INSIGHTS


North America Orphan Drugs Market Size, 2022 (USD billion)

To get more information on the regional analysis of this market, Request a Free sample


In terms of region, the global market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.


In North America, the market size stood at USD 84.59 billion in 2022. The dominance of North America is attributed to the significant expenditure on orphan drugs, strong patient population, and presence of key market players leading to the development of sophisticated and innovative products. For instance, according to the Genetic and Rare Diseases (GARD) Information Center, there are more than 10,000 known rare diseases in the U.S. that affect about 1 in 10 people or 30 million people in the U.S. This factor, coupled with the presence of favorable reimbursement policies in the U.S., is responsible for North America’s dominance in the global market.


The Europe market is anticipated to register a strong CAGR owing to the rising patient population in the region and strong adoption of sophisticated rare disease therapeutics. The market in Asia Pacific is expected to register the highest growth owing to the increasing healthcare expenditure and high awareness of rare diseases. The rest of the world comprises Latin America and the Middle East & Africa, which accounted for a lower share of the global market owing to the under penetration of these medicines in the regions.


KEY INDUSTRY PLAYERS


Strong Portfolio of Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. to Drive Market Growth


The market is highly competitive in nature, owing to the presence of a large number of key market players and their diverse product development pipelines. Currently, Bristol-Myers Squibb Company and F. Hoffmann La Roche Ltd. are dominating the market, accounting for a significant share of the global market in 2022. This is primarily due to the strong sales and product portfolios of oncology-related drugs of these companies.


However, several key players, such as Biogen Inc. and BioMarin Pharmaceutical Inc., with their innovative product pipelines for various rare diseases, are emerging in this industry. Other prominent players include Amgen, Alexion, Novartis, AstraZeneca, DAIICHI SANKYO COMPANY LIMITED, and Agios Pharmaceuticals who also have a significant presence in the global market of novel drugs.


LIST OF KEY COMPANIES PROFILED:



  • Amgen Inc. (U.S.)

  • Bayer AG (Germany)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Alexion Pharmaceuticals Inc. (U.S.)

  • Novo Nordisk A/S (Denmark)

  • Novartis AG (Switzerland)

  • Bristol-Myers Squibb Company (U.S.)

  • AstraZeneca (U.K.)

  • DAIICHI SANKYO COMPANY, LIMITED (Japan)

  • GlaxoSmithKline plc (U.K.)


KEY INDUSTRY DEVELOPMENTS:



  • December 2022 – Amgen Inc. announced its decision to acquire Horizon Therapeutics Plc at a value of USD 27.8 billion along with its orphan drug portfolio.

  • November 2022 – Alexion, a group of AstraZeneca focused on rare diseases, acquired LogicBio Therapeutics, Inc., a pioneering genomic medicine company. This acquisition was made to accelerate Alexion’s growth in genomic medicine while treating rare diseases.

  • March 2022 – Marinus Pharmaceuticals received the U.S. FDA approval for Ztalmy (ganaxolone) that treats seizures associated with rare cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients of two years of age and older.

  • August 2021 – The U.S. FDA accepted a new drug application from Agios Pharmaceuticals, Inc. for mitapivat for the treatment of adults with Pyruvate Kinase (PK) deficiency.

  • May 2021 – The U.S. FDA granted a priority review to BCMA CAR-T cell therapy, an investigational therapy by Legend Biotech Corporation to treat relapsed or refractory multiple myeloma.


REPORT COVERAGE


An Infographic Representation of Orphan Drugs Market

To get information on various segments, share your queries with us



The global research report provides a detailed analysis of the market and focuses on key aspects such as prevalence of major rare diseases in key countries, pipeline review of novel drugs, technological developments, and healthcare spending by key countries in 2019. Besides this, the report offers insights into the latest market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market in recent years.


Report Scope & Segmentation 


























































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 11.6% from 2023 to 2030



Unit



Value (USD billion)



Segmentation



By Therapy Type, Drug Type, Distribution Channel, and Region



By Therapy Type




  • Oncology

  • Hematology

  • Neurology

  • Endocrinology

  • Cardiovascular

  • Respiratory

  • Immunotherapy

  • Infectious Diseases

  • Others



By Drug Type




  • Biologics

  • Non-biologics



By Distribution Channel




  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

  • Others



By Region




  • North America (By Therapy Type, By Drug Type, By Distribution Channel, By Country)

    • U.S.

    • Canada



  • Europe (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Scandinavia

    • Rest of Europe



  • Asia Pacific (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)

    • Japan

    • China

    • India

    • Australia

    • Southeast Asia

    • Rest of Asia Pacific



  • Rest of the World (By Therapy Type, By Drug Type, By Distribution Channel)



Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 156.97 billion in 2022 and is projected to reach USD 368.43 billion by 2030.

In 2022, the North America market stood at USD 84.59 billion.

Recording a CAGR of 11.6%, the market will exhibit steady growth during the forecast period of 2023-2030.

The oncology segment is expected to be the leading segment in this market during the forecast period.

Rising prevalence of rare diseases and increasing R&D of orphan drugs by market players are major factors driving the growth of the market.

Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. are major players of the global market.

North America region dominated the market in 2022.

Launch of advanced product offerings by prominent market players, increasing R&D initiatives, and increased awareness of rare diseases are expected to drive the adoption of orphan drugs in the global market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Jul, 2023
  • 2022
  • 2019-2021
  • 135

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X